Re-evaluation of the contribution of TNFRSF13B variants to antibody deficiency
Journal of Human Immunity · 03.11.2025 · 1 (4)
DOI: 10.70962/jhi.20250016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Human Immunity, online erschienen am 19.08.2025. Verfasst von Hassan Abolhassani und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NCATS NIH HHS, Intramural NIH HHS.
Abstract (Originalsprache)
Predominantly antibody deficiency (PAD) is the most prevalent form of human inborn errors of immunity (IEI). PAD is characterized by recurrent bacterial infections, immune dysregulation, and impaired immunoglobulin production. A monogenic cause of PAD can be identified in about 20% of cases. Approximately 10% of patients carry heterozygous mutations in the tumor necrosis factor receptor superfamily member 13B gene (TNFRSF13B), encoding the B cell surface protein TACI. Heterozygous variants in TNFRSF13B are not sufficient to cause PAD, as ∼1% of the healthy population carries one of these variants. To identify additional genetic contributors to the immune defect in these individuals, we examined the exomes of 161 PAD patients with rare-damaging variants in TNFRSF13B. We identified (1) biallelic mutations in TNFRSF13B, (2) the HLA class II marker (DPA1*03), and (3) multiple single nucleotide polymorphisms in known B cell-related genes as additional genetic risk factors. Moreover, pathogenic mutations in other known IEI genes were presented in 16% of patients with heterozygous TNFRSF13B variants.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
- Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
- Institute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center, Faculty of Medicine, Albert-Ludwigs-University, Freiburg, Germany.
- Clinic for Immunology and Rheumatology, Hannover Medical School, Hanover, Germany.
- RESIST - Cluster of Excellence 2155 to Hanover Medical School, Satellite Center Freiburg, Germany.
- Departments of Medicine and Pediatrics, Division of Allergy and Clinical Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Förderung
- NIAID NIH HHS
- NCATS NIH HHS
- Intramural NIH HHS
- Crafoord Foundation
- Deutsche Forschungsgemeinschaft
- European Commission
- Bundesministerium für Bildung und Forschung
- Wilhelm Sander-Stiftung
Zitieren
APA
Abolhassani, H., Caballero-Oteyza, A., Yang, M., Proietti, M., Delavari, S., Maffucci, P., Schäffer, A. A., Boisson, B., Casanova, J. L., Rezaei, N., Pan-Hammarström, Q., Cunningham-Rundles, C., Hammarström, L., & Grimbacher, B. (2025). Re-evaluation of the contribution of TNFRSF13B variants to antibody deficiency. Journal of Human Immunity, 1(4). https://doi.org/10.70962/jhi.20250016
Vancouver
Abolhassani H, Caballero-Oteyza A, Yang M, Proietti M, Delavari S, Maffucci P, et al. Re-evaluation of the contribution of TNFRSF13B variants to antibody deficiency. Journal of Human Immunity. 2025;1(4). doi:10.70962/jhi.20250016
BibTeX
@article{Abolhassani2025,
author = {Abolhassani, Hassan and Caballero-Oteyza, Andres and Yang, Mingyu and Proietti, Michele and Delavari, Samaneh and Maffucci, Patrick and Schäffer, Alejandro A and Boisson, Bertrand and Casanova, Jean-Laurent and Rezaei, Nima and Pan-Hammarström, Qiang and Cunningham-Rundles, Charlotte and Hammarström, Lennart and Grimbacher, Bodo},
title = {Re-evaluation of the contribution of TNFRSF13B variants to antibody deficiency},
journal = {Journal of Human Immunity},
year = {2025},
volume = {1},
number = {4},
doi = {10.70962/jhi.20250016}
}
EUVIMED